Teclistamab - Guest Lecture

(14:31)

Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma

(8:12)

TECVAYLI (Teclistamab) Everything You Need to Know

(22:21)

Real World Experiences of Patients Treated with Teclistamab | Shonali Midha, MD | IMS 2023

(6:39)

Alfred Garfall: Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma

(6:48)

Teclistamab Approval For Multiple Myeloma Treatment | Ross Firestone, MD, PhD | ASCO 2023

(2:33)

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

(7:3)

Is the bsAb teclistamab safe and effective in patients with relapsed/refractory MM?

(4:28)

Teclistamab in Combination with Sub-Q Daratumumab and Lenalidomide in Myeloma Pts: MajesTEC-2

(6:59)

MajesTEC-2 update: teclistamab plus lenalidomide in R/R multiple myeloma

(45)

2-year follow-up of MajesTEC-1: teclistamab in R/R multiple myeloma

(46)

How Teclistamab Treatment Affects Quality of Life | Rakesh Popat, MD | EHA 2022

(1:46)

Updates on Teclistamab, Talquetamab, and CARVYKTI | Mark Wildgust, PHD | ASH 2022

(5:29)

What Determines Teclistamab Response? | Ross Firestone, MD, PhD | IMS 2023

(2:34)

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results

(9:57)

MajesTEC-1: teclistamab for myeloma

(1:4)

Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab

(4:15)

Durability of Responses With Biweekly Dosing of Teclistamab in Pts With Relapsed/Refractory Myeloma

(5:6)

Approval of teclistamab in triple-class refractory multiple myeloma

(2:4)

Updated Efficacy/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022

(11:22)